Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40

Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Kite Acquires Tmunity Therapeutics

Kite Acquires Tmunity Therapeutics

by | Dec 20, 2022 3:51 pm | Biotechnology

Kite announced on December 20 its acquisition of Tmunity Therapeutics. Kite will acquire all outstanding shares of Tmunity other than those already owned by Kite. The transaction is expected to close in the first quarter of 2023. After closing, Tmunity’s employees will join Kite. The financial terms of the agreement were not disclosed. ​Tmunity is a private, clinical-stage biotechnology company focused on transforming the future of CAR-T therapies by developing the next generation of engineered T-cell therapies, innovative manufacturing processes and technologies. Kite, a clinical-stage biopharmaceutical company, is focused on developing engineered autologous T-cell therapy products. On a... Read More »
PE-Backed Veranex Acquires Fusion Biotec

PE-Backed Veranex Acquires Fusion Biotec

by | Dec 14, 2022 12:55 pm | Biotechnology, Private Equity

Veranex, backed by Summit Partners, Accelmed and Laurexa Capital Partners, has acquired Orange, California-based Fusion Biotec. The combination of Veranex’s infrastructure and experience developing diagnostic services with Fusion’s concept-to-production model works to continue the focus of driving the development of diagnostic and medical technology services for regulatory and commercial use. Financial terms of the deal were not disclosed. Fusion Biotec is a contract engineering and manufacturing firm in southern California dedicated to the diagnostics and medical device industry. Fusion Biotec is ISO 13485 certified for development and manufacturing, FDA and FDB registered. Founded in... Read More »
Kite Acquires Tmunity Therapeutics

Amgen Acquires Horizon Therapeutics in Largest Healthcare Deal of 2022

by | Dec 12, 2022 1:24 pm | Biotechnology

Amgen Inc. announced on December 12 an agreement to acquire Horizon Therapeutics plc in the largest healthcare transaction of the year. Amgen will pay $116.50 for each Horizon share, totaling approximately $27.8 billion. Horizon was advised by Morgan Stanley and JPMorgan Chase & Co. Its legal advisers are Cooley LLP and Matheson LLP.  Amgen’s lead financial adviser is PJT Partners and its financial adviser is Citigroup Inc. Its legal advisers are Sullivan Cromwell LLP and William Fry LLP. Horizon Therapeutics is an Irish biopharmaceutical company focused on developing medicines to treat rare autoimmune and severe inflammatory diseases. The company’s products are sold mostly... Read More »
PE-Backed Veranex Acquires Fusion Biotec

Full-Life Technologies Purchases Focus-X Therapeutics for $245 Million

by | Nov 30, 2022 3:02 pm | Biotechnology

Full-Life Technologies announced on November 28 that it is acquiring Focus-X Therapeutics for $245 million. Founded in 2020, Focus-X created a proprietary engineering platform to develop peptide radioligands that precisely deliver alpha or beta emitters to break down cancer cell DNA. The company is based in Watchung, New Jersey. Shanghai-based Full-Life Technologies Limited is a fully integrated global radiotherapeutics company with operations in Europe and China. It was founded in 2021. The acquisition expands Full-Life’s pipeline, including two compounds nearing clinical trials, and a peptide-focused discovery platform leveraging its radio technology manufacturing and logistics... Read More »
Boston Scientific Acquires Apollo Endosurgery

Boston Scientific Acquires Apollo Endosurgery

by | Nov 30, 2022 1:10 pm | Biotechnology, Medical Devices

Boston Scientific Corp., a biomedical/biotechnology engineering firm and multinational manufacturer of medical devices, announced on November 29 it acquired Apollo Endosurgery in a $615 million deal. Under terms of the deal, Boston Scientific will pay $10 per share to acquire Apollo Endosurgery. Boston Scientific expects to complete the deal in the first half of 2023 and the company expects the acquisition to be accretive to its earnings per share after 2023. Apollo Endosurgery is known for manufacturing medical devices used during endoluminal surgery procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from... Read More »
AstraZeneca Acquires Neogene Therapeutics for up to $320 Million

AstraZeneca Acquires Neogene Therapeutics for up to $320 Million

by | Nov 29, 2022 10:40 am | Biotechnology

AstraZeneca has acquired Neogene Therapeutics in a transaction valued at up to $320 million. Consideration will include an initial payment of $200 million upon closing, and a further amount of up to $120 million in contingent, milestones-based and non-contingent consideration. The transaction is expected to close in the first quarter of 2023. Upon completion of the transaction, Neogene Therapeutics will operate as a wholly owned subsidiary, with operations in Amsterdam, The Netherlands, and Santa Monica, California. Neogene Therapeutics is a clinical-stage biotechnology company focused on discovering, developing and manufacturing transformative TCR therapies targeting neoantigens in solid... Read More »